Insys bankruptcy plan gets court OK

Insys Therapeutics, the first drugmaker to go bankrupt after opioid litigation, won court approval for its bankruptcy plan Jan. 16, The Wall Street Journal reported.

Under the plan, Insys sold the rights to its flagship opioid drug, Subsys, a form of fentanyl. But the money it made from selling its assets wasn't enough to cover its debts, which total more than $1 billion.